Targeted pill shows promise for rare genetic cancers
NCT ID NCT05199584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors shrank and monitored side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENV-101 (taladegib) tablets
What this could lead to
If successful, this could point toward a targeted treatment option for people with certain hard-to-treat cancers that have a specific genetic change.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply broadly. The drug may not shrink tumors or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS WITH PTCH1 LOSS-OF-FUNCTION MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90095, United States
-
Research Site
Santa Rosa, California, 95403, United States
-
Research Site
Tampa, Florida, 33609, United States
-
Research Site
Zion, Illinois, 60099, United States
-
Research Site
Covington, Louisiana, 70433, United States
-
Research Site
Las Vegas, Nevada, 89102, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Durham, North Carolina, 27710, United States
-
Research Site
Cincinnati, Ohio, 45229, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Pittsburgh, Pennsylvania, 15232, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Fredericksburg, Virginia, 22408, United States
-
Research Site
Lynchburg, Virginia, 24501, United States
-
Research Site
Madison, Wisconsin, 53792, United States